Advertisement
Home Tags Heart / Stroke-Related: High Cholesterol

Tag: Heart / Stroke-Related: High Cholesterol

Veterans with type 2 diabetes had durable maintenance of their low-density lipoprotein cholesterol and hemoglobin A1c goals

Maintenance of LDL, HbA1c Goals With Pharmacist-Led Program

0
LDL-C, HbA1c goals maintained after veterans with T2DM discharged from pharmacist-managed clinic
Patients who shared a financial incentive with their doctor to lower their levels of low-density lipoprotein cholesterol achieved a statistically significant reduction after a year of treatment. These findings were published in the Nov. 10 issue of the Journal of the American Medical Association

AHA: ‘Cash for Lower Cholesterol’ Program May Work

0
Cooperation is key to program's success, but benefits are modest
Lipid profiles seem to be associated with tendon health

Review Links Lipid Profiles With Tendon Health

0
Altered tendon structure or pain linked to higher total cholesterol, LDL cholesterol, triglycerides
Migraine frequency and intensity seem to be positively associated with total cholesterol and low-density lipoprotein cholesterol

Migraine Frequency, Intensity Linked to Cholesterol Levels

0
Number and intensity of crises reduced in association with reduction in total, LDL cholesterol
Intestinal microbiomes might help determine not only body fat levels

Gut Microbiome May Play Role in BMI, HDL Cholesterol Levels

0
But more research needed to understand how different bacteria affect risk factors for heart disease
Two newly approved medications to treat high cholesterol are extremely overpriced compared to the health benefits they give to patients

ICER: New Cholesterol Drugs Highly Overpriced

0
Newly FDA-approved Repatha and Praluent currently cost more than $14,000 per year
Repatha (evolocumab) has been approved by the U.S. Food and Drug Administration

FDA Approves Repatha for Certain Patients With High Cholesterol

0
Approved for patients unable to get LDL cholesterol under control with current treatment options
The diabetes drug metformin changes metabolic profiles of three metabolites that may lower LDL cholesterol

Metabolic Changes With Metformin May Lower LDL-C

0
Possible metabolic mechanism includes activation of AMPK, FADS suppression
At lower values of measured low-density lipoprotein cholesterol (LDL-C)

Calculated LDL-C Varies at Lower Values of Measured LDL-C

0
For calculated LDL-C of 30 mg/dL, 95 percent confidence interval was 24 to 60 mg/dL
Praluent (alirocumab) injection has been approved by the U.S. Food and Drug Administration for use in addition to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease

FDA Approves Praluent for Certain Cases of High Cholesterol

0
First in a new class of injectable cholesterol-lowering medications